EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Natural Killer Cell-Based Immunotherapy against Glioblastoma

Takayuki Morimoto iD, Tsutomu Nakazawa iD, Ryosuke Maeoka, Ichiro Nakagawa iD, Takahiro Tsujimura, Ryosuke Matsuda iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24032111 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Takayuki Morimoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Japan. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: a Grand-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults. Despite multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, the median overall survival (OS) after diagnosis is approximately 2 years and the 5-year OS is poor. Considering the poor prognosis, novel treatment strategies are needed, such as immunotherapies, which include chimeric antigen receptor T-cell therapy, immune checkpoint inhibitors, vaccine therapy, and oncolytic virus therapy. However, these therapies have not achieved satisfactory outcomes. One reason for this is that these therapies are mainly based on activating T cells and controlling GBM progression. Natural killer (NK) cell-based immunotherapy involves the new feature of recognizing GBM via differing mechanisms from that of T cell-based immunotherapy. In this review, we focused on NK cell-based immunotherapy as a novel GBM treatment strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsAdultHumansImmunotherapyKiller Cells, NaturalImmunotherapy, AdoptiveTumor Microenvironment

Stichwörter der Autor:innen

NK cellglioblastomaimmunosuppressionimmunotherapytumor microenvironment

Autor:innen und Institutionen

  • Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Japan.
  • Department of Neurosurgery, Nara City Hospital, Nara 630-8305, Japan.
  • Grandsoul Research Institute for Immunology, Inc., Uda 633-2221, Japan.
  • Clinic Grandsoul Nara, Uda 633-2221, Japan.

ORCID-Profile: Takayuki Morimoto, Tsutomu Nakazawa, Ichiro Nakagawa, Ryosuke Matsuda

Förderung

  • a Grand-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan

Zitieren

APA

Morimoto, T., Nakazawa, T., Maeoka, R., Nakagawa, I., Tsujimura, T., & Matsuda, R. (2023). Natural Killer Cell-Based Immunotherapy against Glioblastoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032111

Vancouver

Morimoto T, Nakazawa T, Maeoka R, Nakagawa I, Tsujimura T, Matsuda R. Natural Killer Cell-Based Immunotherapy against Glioblastoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032111

BibTeX
@article{Morimoto2023,
  author = {Morimoto, Takayuki and Nakazawa, Tsutomu and Maeoka, Ryosuke and Nakagawa, Ichiro and Tsujimura, Takahiro and Matsuda, Ryosuke},
  title = {Natural Killer Cell-Based Immunotherapy against Glioblastoma},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24032111}
}
Kostenlos starten →